Medtronic plc MDT

Medtronic plc es una empresa global de tecnología sanitaria. Desarrolla, fabrica y comercializa sus dispositivos médicos y tecnologías a hospitales, médicos, clínicos y pacientes. Sus segmentos operativos incluyen Cardiovascular, Cirugía Médica, Neurociencia y Diabetes. Los productos cardiovasculares incluyen marcapasos, monitores cardiacos insertables y dispositivos de terapia de resincronización cardíaca. Los productos de Cirugía Médica incluyen cuidado al paciente desde el diagnóstico hasta la recuperación, con un enfoque en enfermedades del tracto gastrointestinal, pulmones, región pélvica, riñones, obesidad y complicaciones prevenibles. Los productos de Neurociencia incluyen varios implantes espinales, sustitutos de injertos óseos, productos biológicos, cirugía guiada por imagen y sistemas de imagen intraoperatoria. Los productos de Diabetes incluyen bombas de insulina, sistemas de monitoreo continuo de glucosa (CGM), consumibles y sistemas de bolígrafos inteligentes de insulina. La Compañía también proporciona PROPEL y SINUVA, que son implantes bioabsorbibles y que liberan esteroides para pacientes con sinusitis.

Con 11 acciones de MDT (USD 977,24) habrías recibido USD 31,46 en dividendos en los últimos 12 meses.

• Zacks Investment Research 5 oct

  Medtronic (MDT) Outperforms Broader Market: What You Need to Know

  Medtronic (MDT) closed at $87.97, up 1.84% in recent trading. The medical device company is projected to report EPS of $1.34 (down 1.47% YoY) and revenue of $9.47 billion (up 5.63% YoY). For the full year, analysts expect EPS of $5.98 and revenue of $38.96 billion. MDT carries a Zacks Rank #3 (Hold) with a Forward P/E of 14.45, trading at a discount to its industry average of 19.67.

  

• The Motley Fool 5 oct

  Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October

  Despite recent Fed rate hikes and rising Treasury yields, the article recommends two blue chip dividend stocks: AbbVie, a Dividend King with 53 consecutive years of dividend increases and strong growth prospects from new drugs, and Medtronic, which is on track to become a Dividend King with 49 consecutive years of dividend hikes and improving operational performance after recent restructuring.

  

• The Motley Fool 4 oct

  2 High-Yield Stocks to Buy in October Without Any Hesitation

  The author recommends two high-yield dividend stocks for October: Medtronic (MDT), which has completed a business overhaul and is approaching Dividend King status with a 3.3% yield, and McCormick (MKC), a consumer staples company with 39 years of dividend increases and a 4.2% yield that is acquiring Unilever's food business to roughly double its sales.

  

• The Motley Fool 3 oct

  Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way.

  As Wall Street anticipates potential Fed rate hikes, healthcare stocks are positioned to weather economic uncertainty better than other sectors. Three healthcare companies—Eli Lilly, Medtronic, and Johnson & Johnson—are highlighted as resilient investments due to their strong fundamentals, diversified portfolios, and proven ability to generate growth regardless of interest rate environment.

  

• Zacks Investment Research 2 oct

  Can ISRG Offset China Weakness With Expansion in India and Japan?

  Intuitive Surgical faces headwinds in China due to weak tenders, domestic competition, and pricing pressure, with only two systems placed. However, the company is diversifying growth through strong momentum in India following da Vinci 5 clearance and improved conditions in Japan with new reimbursement policies supporting 25 system placements. International da Vinci procedures grew 20% in Q2, with management maintaining its 2026 procedure growth outlook of 13.5-15.5%.